Systematic review of 15 observational studies (11 meta-analysed; 264,286 infants): nirsevimab was associated with lower odds of LRTI hospitalisation (OR 0.38) and LRTI ED visits (OR 0.52); no significant difference in all-cause hospitalisation.
Meta-analysisn = 264,286
Sumsuzzman et al. Nirsevimab Against Hospitalizations and Emergency Department Visits for Lower Respiratory Tract Infection in Infants: A Meta-Analysis